Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Opthea ( (AU:OPT) ).
Opthea Limited announced the cessation of Quinton Oswald as a director effective June 2, 2025. This change in the board may influence the company’s strategic direction, particularly in its ongoing development of treatments for eye diseases. Oswald held significant unquoted options, which may impact stakeholder interests and the company’s financial strategies moving forward.
The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited operates in the biotechnology industry, focusing on the development of therapies for eye diseases. The company is known for its innovative approaches to treating conditions such as wet age-related macular degeneration and diabetic macular edema.
YTD Price Performance: -25.93%
Average Trading Volume: 6,651,653
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
See more data about OPT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue